Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company
April 7, 2025
Highlights The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets ...
Harnessing the power of IgE in Oncology
Why IgE?
IgE evolved to kill multicellular tissue-dwelling parasites. Epsilogen is harnessing this power to kill solid tumours
MOv18 IgE
MOv18 IgE targets ovarian cancer and is the first therapeutic IgE antibody to enter clinical trials.
IgEGs
Epsilogen has used its IgE expertise to build a fusion antibody combining the best of IgE and IgG
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life.
The company’s lead product candidate, MOv18 IgE, has successfully completed a phase I clinical trial in folate receptor alpha positive cancer patients. This is the world’s first IgE drug to enter clinical trials. MOv18 IgE was found to be safe and well tolerated with early signs of clinical activity seen.
https://www.nature.com/articles/s41467-023-39679-9
Epsilogen has constructed a novel and proprietary pipeline of anti-cancer IgE and IgE-derivative antibodies with enhanced functionality.
Recent Press Releases
Epsilogen announces initiation of Phase Ib trial of MOv18 IgE
December 3, 2024
Proof-of-concept study to evaluate the safety, tolerability and efficacy of MOv18 IgE in patients with ...
